| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RAC Overview
Race Oncology Limited operates as a precision oncology company in Australia.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.16 |
| 52 Week High | AU$0.91 |
| 52 Week Low | AU$4.23 |
| Beta | 1.92 |
| 1 Month Change | -10.99% |
| 3 Month Change | -11.98% |
| 1 Year Change | 230.89% |
| 3 Year Change | 2,240.74% |
| 5 Year Change | 1,164.00% |
| Change since IPO | 1,092.45% |
Recent News & Updates
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Race...
Shareholder Returns
| RAC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -0.6% | 2.3% | 0.9% |
| 1Y | 230.9% | 1.5% | 20.2% |
Return vs Industry: RAC exceeded the Australian Biotechs industry which returned 1.5% over the past year.
Return vs Market: RAC exceeded the Australian Market which returned 20.2% over the past year.
Price Volatility
| RAC volatility | |
|---|---|
| RAC Beta | 1.92 |
| Industry Beta | 1.61 |
| Market Beta | 1 |
Stable Share Price: RAC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: RAC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Phil Lynch | https://www.raceoncology.com |
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein for treating for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene.
Race Oncology Fundamentals Summary
| RAC fundamental statistics | |
|---|---|
| Market Cap | AU$473.34m |
| Earnings (TTM) | -AU$6.34m |
| Revenue (TTM) | AU$387.39k |
1.2kx
P/S Ratio-73.0x
P/E RatioIs RAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAC income statement (TTM) | |
|---|---|
| Revenue | AU$387.39k |
| Cost of Revenue | AU$620.08k |
| Gross Profit | -AU$232.69k |
| Expenses | AU$6.11m |
| Earnings | -AU$6.34m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.043 |
| Gross Margin | -60.07% |
| Net Profit Margin | -1,636.70% |
| Debt/Equity Ratio | 0.0% |
How did RAC perform over the long term?
See historical performance and comparisonValuation
Is Race Oncology undervalued compared to its fair value and its price relative to the market?
33.75x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RAC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RAC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RAC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: RAC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RAC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RAC is overvalued based on its PB Ratio (33.7x) compared to the AU Biotechs industry average (4.9x).
Future Growth
How is Race Oncology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
11.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Race Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Race Oncology performed over the past 5 years?
-11.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RAC is currently unprofitable.
Growing Profit Margin: RAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RAC is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare RAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: RAC has a negative Return on Equity (-46.2%), as it is currently unprofitable.
Financial Health
How is Race Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: RAC's short term assets (A$10.6M) exceed its short term liabilities (A$523.1K).
Long Term Liabilities: RAC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RAC is debt free.
Reducing Debt: RAC has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RAC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RAC has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 23.5% each year.
Dividend
What is Race Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RAC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Phil Lynch
1.08yrs
Tenure
AU$4,000
Compensation
Mr. Phillip R. Lynch, also known as Phil, has been a Non-Executive Director of Race Oncology Limited since June 1, 2020 and has been its Chief Executive officer and Managing Director since September 2, 202...
Leadership Team
Experienced Management: RAC's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Experienced Board: RAC's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RAC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.9%.
Top Shareholders
Company Information
Race Oncology Limited's employee growth, exchange listings and data sources
Key Information
- Name: Race Oncology Limited
- Ticker: RAC
- Exchange: ASX
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$473.340m
- Shares outstanding: 146.54m
- Website: https://www.raceoncology.com
Location
- Race Oncology Limited
- Gateway, 1 Macquarie Place
- Level 36
- Sydney
- New South Wales
- 2000
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/18 07:04 |
| End of Day Share Price | 2021/10/18 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.